Results of the phase 2, open-label, single-arm S-OLARIS study provide ‘proof of concept’ that the novel IL-17A/F-inhibiting nanobody has an effect on patients with axial spondyloarthritis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/promising-results-novel-nanobody-sonelokimab-early-phase-2026a1000k7q?src=rss
Author :
Publish date : 2026-06-16 08:52:00
Copyright for syndicated content belongs to the linked Source.